It’s someone else’s company again!
In order to enable employees to achieve common prosperity, Chongqing billionaire Jiang Rensheng transferred his 28.78 million Chongqing Zhifei Biological Products Co.Ltd(300122) shares to the company’s employee stock ownership plan at the price of 100 yuan / share.
it is worth mentioning that the transfer price of 100 yuan / share is 16.77% lower than the latest share price of Chongqing Zhifei Biological Products Co.Ltd(300122) 120.15 yuan / share, and the number of participants in the employee stock ownership plan is as high as 2000. This means that 2000 employees invested 2.878 billion yuan to buy Chongqing Zhifei Biological Products Co.Ltd(300122) shares. The latest market value of these shares is 3.458 billion yuan. The employees have a total floating profit of 580 million yuan and a per capita floating profit of 290000 yuan
However, it should be noted that although the current situation is floating profit, the company’s share price fluctuates, and there is no guarantee that it will make money in the future, because the shares held by the employee stock ownership plan have a lock-in period of 12 months. After the lock-in expires, the management committee and the management organization will decide whether to sell the shares according to the arrangement of the employee stock ownership plan and the market conditions.
The per capita floating profit is 290000 yuan! 2000 employees participate in Chongqing Zhifei Biological Products Co.Ltd(300122) shareholding plan
Recently, China’s leading vaccine stock Chongqing Zhifei Biological Products Co.Ltd(300122) , with a market value of more than 190 billion, has seen four huge block transactions, with a total of 28.78 million shares, all of which are more than 16% lower than the secondary market price, which has attracted the attention of investors.
Specifically, on March 10, Chongqing Zhifei Biological Products Co.Ltd(300122) appeared two block transactions with a total discount of 1.58 billion yuan, with a transaction price of 100 yuan / share. A total of 15.8 million shares were traded, 16.23% lower than the closing price of the day, and the discount amount reached 306 million yuan. The seller is Shenwan Hongyuan Group Co.Ltd(000166) Lishui Chengda Street business department, and the buyer is Chongqing Vientiane City Business Department of Galaxy Securities.
On March 14, Chongqing Zhifei Biological Products Co.Ltd(300122) another block transaction with a discount of 1.298 billion yuan occurred, with a transaction price of 100 yuan / share, a total of 12.98 million shares were traded, 16.77% lower than the closing price of the day, and the discount amount reached 262 million yuan. The seller is still Shenwan Hongyuan Group Co.Ltd(000166) Lishui Chengda Street business department, and the buyer is still Chongqing Mixc securities business department of Galaxy Securities.
The transfer of shares at such a huge discount makes many investors feel strange. However, on the 14th, the answer was finally revealed. It turned out that Jiang Rensheng, the controlling shareholder of the company, sold the above shares to employees at a low price.
On March 14, Chongqing Zhifei Biological Products Co.Ltd(300122) announced that the controlling shareholder Jiang Rensheng transferred 28.78 million shares of the company through block trading, accounting for 1.80% of the total share capital of the company, and the transferee was the employee stock ownership plan of the company (2022).
It is worth mentioning that the transfer price of 100 yuan / share is 16.77% lower than Chongqing Zhifei Biological Products Co.Ltd(300122) latest share price (120.15 yuan / share), and the number of participants in the employee stock ownership plan is as high as 2000. This means that 2000 employees invested 2.878 billion yuan together and purchased Chongqing Zhifei Biological Products Co.Ltd(300122) 2878 million shares from Jiang Rensheng. The latest market value of these shares was 3.458 billion yuan. The total floating profit of 2000 employees was 580 million yuan and the per capita floating profit was 290000 yuan.
Chongqing Zhifei Biological Products Co.Ltd(300122) plans to promote common prosperity through employee stock ownership plan
Looking back, on February 11, Chongqing Zhifei Biological Products Co.Ltd(300122) disclosed the draft of the company’s employee stock ownership plan for common prosperity (2022) (updated version). The participants are the core backbone employees of the company and its subsidiaries, with a total number of no more than 2000.
The employee stock ownership plan will raise no more than 1.6 billion yuan, and the total planned share will not exceed 1.6 billion. Among them, 14 directors, supervisors and senior executives of the company participated in the employee stock ownership plan, with a total subscription share of no more than 542 million; The total subscription shares of other employees shall not exceed 1.058 billion.
After the establishment of the employee stock ownership plan, professional institutions will be entrusted to manage it, and it is planned to finance in a ratio of no more than 1:1 (that is, the participating employees should double the leverage), and the upper limit of the management scale is 3.2 billion yuan.
On February 14, Chongqing Zhifei Biological Products Co.Ltd(300122) extraordinary general meeting of shareholders deliberated and approved relevant proposals of employee stock ownership plan (2022); On February 21, Chongqing Zhifei Biological Products Co.Ltd(300122) entrusted Shanghai Yingshui Investment Management Co., Ltd. to manage the employee stock ownership plan, and signed the private securities investment fund contracts of Yingshui Heli No. 9, 11 and 13 respectively.
Then, on March 10 and March 14, the above ESOP transferred Chongqing Zhifei Biological Products Co.Ltd(300122) 2878 million shares held by Jiang Rensheng through block trading.
For the purpose of the ESOP, Chongqing Zhifei Biological Products Co.Ltd(300122) said that the ESOP can effectively promote the company to implement a long-term and stable talent development strategy, highlight the concept of common and sustainable development of the company and individuals, and mobilize the enthusiasm of managers and employees; Under the background of common prosperity, ESOP also actively promotes the balance between shareholders’ interests and employees’ interests and common prosperity.
In March 2016 and June 2019, Chongqing Zhifei Biological Products Co.Ltd(300122) successively launched the first phase and the second phase of ESOP, with 500 and 800 employees respectively. Among them, 10.01 million shares held in the first phase of the employee stock ownership plan were sold in December 2017, and 16.15 million shares held in the second phase of the employee stock ownership plan were sold from August 11, 2020 to September 1, 2021. Employees participating in the above two stock ownership plans have obtained very considerable investment income.
2021 net profit exceeds 10 billion, with continuous good news
Chongqing Zhifei Biological Products Co.Ltd(300122) is a biological high-tech enterprise integrating the R & D, production, promotion, sales, distribution, import and export of vaccines and biological products. It was listed on the Shenzhen Stock Exchange in September 2010. It is the first private vaccine enterprise listed on the gem.
The company sells products including recombinant New Coronavirus vaccine (CHO cell) (chi Ke Wei), recombinant Mycobacterium tuberculosis fusion protein (EC, Yi card), ACYW135 group meningococcal polysaccharide vaccine (menwick), A group C group meningococcal polysaccharide conjugate vaccine (Haemophilus influenza type B conjugates Vaccine), Haemophilus influenza type B conjugates Vaccine (Xi Feibei), Mycobacterium vaccae for Injection (micro card) and other independent products. And uniformly sell all imported vaccines such as tetravalent human papillomavirus vaccine (Saccharomyces cerevisiae), nine valent human papillomavirus vaccine (Saccharomyces cerevisiae), oral pentavalent reconstituted rotavirus attenuated live vaccine (Vero cells), 23 valent pneumococcal polysaccharide vaccine, hepatitis A inactivated vaccine (human diploid cells) and so on.
In recent years, Chongqing Zhifei Biological Products Co.Ltd(300122) performance has maintained rapid growth. From 2017 to 2020, the operating revenue of the company was 1.343 billion yuan, 5.228 billion yuan, 10.587 billion yuan and 15.190 billion yuan respectively, and the net profit attributable to the parent company was 432 million yuan, 1.451 billion yuan, 2.366 billion yuan and 3.301 billion yuan respectively.
According to the latest performance express, in 2021 Chongqing Zhifei Biological Products Co.Ltd(300122) achieved a revenue of 30.637 billion yuan, a year-on-year increase of 101.68%, and a net profit of 10.197 billion yuan, a year-on-year increase of 208.88%. During the reporting period, the sales of the company’s independent products and agent products continued to increase steadily.
Recently, Chongqing Zhifei Biological Products Co.Ltd(300122) ‘s good news keeps coming. The company announced in March 2nd that the recombinant New Coronavirus protein vaccine (CHO cell), which was jointly developed by Chi Fei Long Ma, a wholly owned subsidiary of China and the Institute of Microbiology of the Chinese Academy of Sciences, was granted conditional listing.
Recombinant COVID-19 protein vaccine is the first approved recombinant COVID-19 virus protein vaccine, which is suitable for preventing New Coronavirus infection (COVID-19). Chongqing Zhifei Biological Products Co.Ltd(300122) said that the company will continue to do a good job in the production and supply of the vaccine with quality and quantity. If the follow-up work goes smoothly, it will promote the WHO certification of the vaccine and its sequential (heterologous) vaccination, and will also have a positive impact on the future performance, research and development progress and internationalization strategy of listed companies.
On February 11, Chongqing Zhifei Biological Products Co.Ltd(300122) announced that the freeze-dried recombinant tuberculosis vaccine (AEC / bc02) developed by the wholly-owned subsidiary zhifeilong Kema has completed phase I clinical research, and the preliminary results show that the vaccine has good safety and tolerance. At present, the preparation of phase IIa clinical trial of the product has been completed, the subject screening has been started, and the phase IIa clinical trial has been officially launched.
The freeze-dried recombinant tuberculosis vaccine (AEC/BC02) is intended to be used for the prevention of tuberculosis in people aged 18 or above with latent infection of Mycobacterium tuberculosis. It belongs to 1 categories of biological products for prevention. At present, there is no similar vaccine on the market outside China.
Judging from the stock price trend of the secondary market, in May last year, Chongqing Zhifei Biological Products Co.Ltd(300122) hit a record high of 231.19 yuan / share, more than 24 times higher than the low point in early September 2015, and the market value approached 370 billion yuan at the peak. However, from May 18, 2021 to the end of January 2022, the company’s share price corrected by nearly 53%. Since February, the company’s share price has rebounded, with the latest market value of 192.2 billion yuan.
